| Subject: | FDA Issues Statement Regarding Withdrawal of PharMEDium's Lot of IV Magnesium Sulfate |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Wed, 23 Mar 2005 - 10:00 am |
| The FDA and PharMEDium Services have issued a notification regarding the withdrawal of one lot of PharMEDium's Magnesium Sulfate intravenous solution - 1 (one) gram in 50 mL D5W, in IV piggyback form. The FDA and PharMEDium state that the lot may be contaminated with Serratia marcescens. Magnesium Sulfate is often administered to individuals undergoing cardiac procedures. This medication was distributed to several hospitals in the United States, and to date there have been five (5) recent cases... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
Related MCN Products:
|
|
StayAlert!® Virtual Compliance Administrator™ keeps clients informed by email of any changes to Federal regulations, including Joint Commission (TJC, formerly JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG, and many more, and also provides downloadable tools to ensure compliance. StayAlert! is a premium product sold as an annual site-license subscription. With the site license, the client can sign up an unlimited number of users for the email alerts and access to the StayAlert! online regulatory library. The strength of StayAlert! rests in its ability to allow healthcare organizations to streamline their businesses using the Internet as a foundation architecture. StayAlert! provides cost containment and reduction through elimination of unnecessary overhead, and work caused by errors or poor access to information. |
|
